Compare drug alternatives
Trelegy Ellipta ® Alternatives
Trelegy Ellipta ®(Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate) | Yupelri ®(Revefenacin) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Dosing | |
Latin Shorthand | |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $0. Learn more. |
Annual Cap | |
$6,660. Learn more. | |
Assistance Expiration | |
12/31/2023. Learn more. | Calendar year. Learn more. |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
COPD: Most common adverse reactions (incidence ≥1%) are upper
respiratory tract infection, pneumonia, bronchitis, oral candidiasis,
headache, back pain, arthralgia, influenza, sinusitis, pharyngitis, rhinitis,
dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis,
oropharyngeal pain, cough, and dysphonia. (6.1)
Asthma: Most common adverse reactions (incidence ≥2%) are
pharyngitis/nasopharyngitis, upper respiratory tract infection/viral upper
respiratory tract infection, bronchitis, respiratory tract infection/viral
respiratory tract infection, sinusitis/acute sinusitis, urinary tract infection,
rhinitis, influenza, headache, and back pain.. Learn more. | Most common adverse reactions (incidence greater than or equal to 2% and more common than placebo) include cough, nasopharyngitis, upper respiratory tract infection, headache, and back pain.. Learn more. |
Mechanism of Actions (MoA) | |
Anticholinergics . Learn more. | Anticholinergics. Learn more. |
Special Populations | |
8.1 Pregnancy Risk Summary Insufficient data are available on the use of TRELEGY ELLIPTA or its individual components (fluticasone furoate, umeclidinium, and vilanterol) in pregnant women to determine a drug-associated risk. Animal studies showed no adverse effects on embryofetal development for these components at exposures approximately 4.5 to 200 times the maximum recommended daily inhalation doses in adults. 8.2 Lactation Risk Summary No information is available on the presence of these components in human milk, their effects on the breastfed child, or milk production. Umeclidinium was detected in the plasma of offspring of lactating rats treated with umeclidinium, suggesting its presence in maternal milk. 8.4 Pediatric Use TRELEGY ELLIPTA is not approved for use in pediatric patients, and its safety and efficacy in pediatric patients have not been established. 8.5 Geriatric Use No dosage adjustment is necessary for geriatric patients, but greater sensitivity in some older individuals cannot be ruled out. 8.6 Hepatic Impairment TRELEGY ELLIPTA has not been studied in subjects with hepatic impairment. Information on the individual components is provided. 8.7 Renal Impairment TRELEGY ELLIPTA has not been studied in subjects with renal impairment. Information on the individual components is provided. | 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with YUPELRI in pregnant women. If a woman becomes pregnant while taking YUPELRI, it is advisable to contact their physician. Animal reproduction studies showed no evidence of fetal harm at exposures up to 209 times the maximum recommended human dose. 8.2 Lactation Risk Summary There is no information available regarding the presence of revefenacin in human milk or its effects on breastfed infants. However, revefenacin was found in the milk of lactating rats. The decision to breastfeed should consider both the benefits of breastfeeding and the clinical need for YUPELRI, weighing potential effects on the infant from YUPELRI or the mother's underlying condition. 8.4 Pediatric Use The safety and effectiveness of YUPELRI have not been established in pediatric patients, and it is not indicated for use in children. 8.5 Geriatric Use Available data indicate no need for dosage adjustment in geriatric patients. Clinical trials included subjects aged 65 years and older, with no overall differences in safety or effectiveness observed between these subjects and younger subjects. 8.6 Hepatic Impairment Revefenacin exposure remains unchanged in subjects with hepatic impairment, while the active metabolite's exposure increases. YUPELRI's safety has not been evaluated in COPD patients with hepatic impairment and is not recommended for patients with any degree of hepatic impairment. 8.7 Renal Impairment No dosage adjustment is necessary for patients with renal impairment. However, COPD patients with severe renal impairment should be monitored for systemic antimuscarinic side effects. |